^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PD-1 overexpression

i
Other names: PD1, Programmed Cell Death Protein 1, CD279, SLEB2, PD-1, Programmed cell death 1, PDCD1, Systemic Lupus Erythematosus Susceptibility 2
Entrez ID:
Related biomarkers:
19d
Increased PD-1 expression on circulating T-cells correlates with inferior outcome after autologous stem cell transplantation. (PubMed, Transplant Cell Ther)
PD-1 expression on T-cells might serve as an adverse biomarker for lymphoma patients undergoing autologous stem cell transplantation, however further validation by larger prospective studies is required.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • HK2 (Hexokinase 2)
|
PD-1 overexpression • PD-1 expression • PD-1-L • PD-1 underexpression
2ms
IL-32 production from lung adenocarcinoma cells is potentially involved in immunosuppressive microenvironment. (PubMed, Med Mol Morphol)
In conclusion, IL-32 potentially induced by inflammatory conditions and anticancer therapy and contribute to immune escape of cancer cells via development the immunosuppressive microenvironment. IL-32 might be a target molecule for anti-cancer therapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • IL32 (Interleukin 32)
|
PD-1 overexpression • PD-1 expression • IFNG expression
2ms
Biomimetic Responsive Nanoconverters with Immune Checkpoint Blockade Plus Antiangiogenesis for Advanced Hepatocellular Carcinoma Treatment. (PubMed, ACS Appl Mater Interfaces)
Our strategy employed pH-responsive carriers, poly(ethylene glycol)-poly(β-amino esters) amphiphilic block copolymer (PEG-PAEs), for delivering apatinib (an angiogenesis inhibitor), that were surface-coated with plasma membrane derived from engineered cells overexpressing PD-1 proteins (an immune checkpoint inhibitor to block PD-L1)...Importantly, our nanomedicine selectively accumulated in both small and large HCC occupying >50% of the liver volume to exert therapeutic effects with minimal systemic side effects. Overall, these findings highlight the potential of such multifunctional nanoconverters to effectively reshape the tumor microenvironment for advanced HCC treatment.
Journal • Checkpoint inhibition • Checkpoint block • Metastases
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)
|
PD-1 overexpression
|
AiTan (rivoceranib)
4ms
Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model. (PubMed, Front Immunol)
However, we found no advantage for anti-PD-1 against PD-1 high expressing Vδ2 T cells in promoting pyroptosis. Taken together, our work demonstrated that Vδ2 T cells combined with anti-PD-1 antibody can be developed as a potential combination immunotherapy for mesothelioma.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-L2 (Programmed Cell Death 1 Ligand 2) • IL2 (Interleukin 2) • CASP3 (Caspase 3) • IL18 (Interleukin 18) • BTN2A1 (Butyrophilin Subfamily 2 Member A1) • IL1B (Interleukin 1, beta) • BTN3A1 (Butyrophilin Subfamily 3 Member A1) • GSDME (Gasdermin E)
|
PD-1 overexpression • PD-L2 expression
4ms
A transcriptomic approach to explore the immune landscape of patient with pancreatic ductal adenocarcinoma with prognostic impact. (ASCO-GI 2024)
In this study, a prognostic transcriptomic-based signature of 14 genes has been defined and validated for PDAC. This signature clearly identifies two prognostic groups that could constitute the basis for tailored immunotherapy with specific IC inhibitors. LAG-3 is a promising target for immunotherapy in PDAC patients.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule) • TBX21 (T-Box Transcription Factor 21) • BTLA (B And T Lymphocyte Associated) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
|
PD-1 overexpression • PD-1 expression • LAG3 overexpression
|
HTG EdgeSeq Precision Immuno-Oncology Panel
4ms
Tumor microenvironment in Hodgkin lymphoma: novel prognostic factors for assessing disease evolution. (PubMed, J Med Life)
The analysis of the data collected in this paper highlights several key parameters with prognostic value and statistical significance: the EBV infection at diagnosis, its association with low-intensity BCL2(+), the presence of CD68 with rosette formation, and the identification of specific vascularization patterns. The development of prognostic systems that take into account the integration of biological prognostic markers seems essential for a better risk stratification.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • PD-1 (Programmed cell death 1) • CD68 (CD68 Molecule)
|
BCL2 overexpression • PD-1 overexpression • PD-1 expression
5ms
PD-1 Expression in Lymphoma Cells Mediates Cellular Proliferation By Engaging Phosphatase SHP-1/SHP-2 (ASH 2023)
Our group showed a selective response (~40%) with the PD-1 blocking antibody pembrolizumab in patients with RT, particularly after prior exposure to ibrutinib (Ding et al, Blood, 2017)...SHP-1 (TPI-1) and SHP-1+SHP-2 (TPI-1+TNO155) inhibitor treatment promoted OCI-LY19 cell death and led to recovery of phosphorylation on ATM, Chk-2 and p53 in these cells... Our data showed robust PD-1 expression in patients with Richter transformation from CLL to DLBCL. PD-1 overexpression in DLBCL lymphoma cell lines enhanced cell proliferation in vitro and in vivo. Further investigation identified that PD-1 modified the phosphorylation/function of SHP phosphatases and thereby regulated p53 pathways (Figure 1).
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CHEK2 (Checkpoint kinase 2) • PD-L2 (Programmed Cell Death 1 Ligand 2) • LY9 (Lymphocyte Antigen 9)
|
PD-1 overexpression • PD-1 expression
|
Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • batoprotafib (TNO155)
6ms
PROGNOSTIC VALUE OF EXPRESSION OF PD-1 AND CTLA-4 IN PERIPHERAL BLOOD IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (AASLD 2023)
In this study, we have demonstrated that the genes associated with immune checkpoint genes can be utilized as a prognostic biomarker for HCC. Notably, PD-1 gene expression in PBMCs has a great potential for estimating survival outcomes of patients with HCC.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • AFP (Alpha-fetoprotein)
|
PD-1 overexpression • PD-1 expression • CTLA4 expression • PD-1-L
6ms
Independent prognostic biomarker FERMT3 associated with immune infiltration and immunotherapy response in glioma. (PubMed, Ann Med)
Multiple immunofluorescence staining confirmed the overexpression of Kindlin-3 in the glioma-associated microglia/macrophages (GAMs). The findings of this study provide a new perspective on the role of Kindlin-3 in glioma and may have a significant impact on the discovery of novel biomarkers and targeting of GAMs in the future.
Journal • PD(L)-1 Biomarker • IO biomarker
|
FERMT3 (FERM Domain Containing Kindlin 3)
|
PD-1 overexpression
6ms
Clinical Staphylococcus aureus inhibits human T-cell activity through interaction with the PD-1 receptor. (PubMed, mBio)
Moreover, we find that blocking the specific receptor (PD-1) using antibodies significantly relieves the S. aureus-imposed inhibition. Our findings suggest that therapeutically targeting PD-1 is a possible future strategy for treating certain antibiotic-resistant staphylococcal infections.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • IL2RA (Interleukin 2 receptor, alpha)
|
PD-1 overexpression • IL2RA expression • IL2 expression
7ms
Cuproptosis-immunotherapy using PD-1 overexpressing T cell membrane-coated nanosheets efficiently treats tumor. (PubMed, J Control Release)
Unfortunately, the well-known cuproptosis initiator, disulfiram and copper complex (DSF/Cu), also increases PD-L1 level in tumors, which may diminish the final therapeutic outcome...After CuX-P treatment with laser irradiation, strong anti-tumor immune responses are stimulated in a mouse model with triple-negative breast cancer. Thus, this study develops a tumor-targeted biomimetic system that offers simultaneous cuproptosis killing, photothermal therapy (PTT) and immunotherapy in mice.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1)
|
PD-L1 expression • PD-1 overexpression
7ms
Study of PD1 and PDL1 Expression in Cutaneous T‑Cell Lymphomas (SOHO 2023)
In this study, we report the PD-1 expression as a tool for differential diagnosis between SS and other etiologies, including MF, and between early stages of MF and BID. Also, it was noted that the detection high expression of PDL-1 correlates with an unfavorable form of the disease. That is, in all cases of SS, a comparable high expression of both PD-1 and PDL-1 was noted, which also affects the aggressive course of the disease.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • PD-L1 overexpression • PD-1 overexpression • PD-1 expression
7ms
Cholesterol removal improves performance of a model biomimetic system to co-deliver a photothermal agent and a STING agonist for cancer immunotherapy. (PubMed, Nat Commun)
In summary, we develop a simple, effective, safe and widely-applicable biological membrane modification strategy. This "subtractive" strategy displays some advantages and is worth further development.
Journal
|
PD-1 (Programmed cell death 1)
|
PD-1 overexpression
7ms
Mesonephric-like Adenocarcinoma of the Uterine Corpus: Genomic and Immunohistochemical Profiling with Comprehensive Clinicopathological Analysis of 17 Consecutive Cases from a Single Institution. (PubMed, Biomedicines)
Our observations consolidated the clinicopathological and molecular characteristics of uterine MLA. Both clinicians and pathologists should consider these features to make an accurate diagnosis of uterine MLA and to ensure appropriate therapeutic management of this rare entity.
Journal
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog)
|
TP53 mutation • KRAS mutation • PD-L1 overexpression • PD-1 overexpression • KRAS deletion
8ms
Expression and clinical significance of PD-1 in UCEC and its Impact on tumor. (PubMed, Cell Mol Biol (Noisy-le-grand))
The prognosis of UCEC patients with PD1 overexpression phenotype is worse than that of the PD1 low group, which is due to the involvement of the PD1 gene in the T-cell receptor signaling pathway. This study provides a further theoretical basis and reference for targeted therapy against PD1.
Journal • PD(L)-1 Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • MUC16 (Mucin 16, Cell Surface Associated) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • TTN (Titin) • FASLG (Fas ligand) • TNFRSF9 (TNF Receptor Superfamily Member 9) • ICOS (Inducible T Cell Costimulator) • CD3D (CD3d Molecule) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)
|
TP53 mutation • PIK3CA mutation • PTEN mutation • PD-1 overexpression • PD-1 expression • PD-1-L
8ms
Synthesis and Evaluation of Lu-DOTA-PD-L1-i and Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy. (PubMed, Int J Mol Sci)
In the case of Lu-DOTA-PD-L1-i, the radiation dose delivered to the lung micrometastases was ten times (43 mGy/MBq) that delivered to the kidneys (4.20 mGy/MBq) and fifty times that delivered to the liver (0.85 mGy/MBq). Therefore, the radiotherapeutic PD-L1-i ligands of Ac and Lu developed in this research could be combined with immunotherapy to enhance the therapeutic effect in various types of cancer.
Journal
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-1 overexpression
8ms
Does IgG4-related disease impact on metastasis?- a case of disseminated cutaneous metastasis of laryngeal squamous cell carcinoma. (EADV 2023)
This gentleman’s complex medical background included; multisystemic IgG4 related disease involving the liver, lung and oesophagus requiring; oseophagectomy and gastric transposition; and medical management with Azathioprine and Prednisolone. Due to role of PD-1, would Cemiplimab6 have been an option for treatment in this patient with IgG4 malignancy?
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 overexpression • PD-1 overexpression • PD-1 expression
|
Libtayo (cemiplimab-rwlc)
8ms
Influence of body mass index (BMI) on the response to chemotherapy in patients with HER2+ breast cancer: Role of the leptin axis (ESMO 2023)
Conclusions Our study shows for the first time how obesity, through the Ob-R/leptin axis, might activate TILs. However, this was not translated into higher CR; probably due to high PD-1 expression as exhaustion feature.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-1 (Programmed cell death 1) • LEP (Leptin)
|
HER-2 expression • PD-1 overexpression • PD-1 expression
8ms
Obesity Promotes Lung Carcinogenesis Through T-cell Immune Dysfunction (IASLC-WCLC 2023)
We demonstrate that obesity is associated with lung carcinogenesis in both clinical cohorts as well as preclinical models, refuting the concept of an obesity paradox for lung carcinogenesis. This phenomenon is associated with Treg and CD8+ T cell exhaustion related immunosuppression in the lung. This finding highlights the importance of addressing obesity in patients at risk for lung cancer.
PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
|
PD-1 overexpression • PD-1 expression
8ms
GPD1 inhibits the carcinogenesis of breast cancer through increasing PI3K/AKT-mediated lipid metabolism signaling pathway. (PubMed, Heliyon)
The inhibitory effect of GPD1 on breast cancer cells was also weakened after treatment with LY294002, a PI3K/AKT pathway inhibitor...Meanwhile, we detected that the relationship between GPD1 level and survival rate presents a positive correlation in breast cancer patients from the Cancer Genome Atlas (TCGA) database. Therefore, GPD1 can be a prognostic biomarker and target in developing therapeutic strategies for breast cancer patients.
Journal
|
PD-1 overexpression
|
LY294002
8ms
C. tropicalis promotes CRC by down-regulating tumor cell-intrinsic PD-1 receptor via autophagy. (PubMed, J Cancer)
tropicalis) can promote CRC tumor growth and chemotherapy resistance to oxaliplatin by regulating mismatch repair system...tropicalis can down-regulate tumor cell-intrinsic PD-1 expression via enhancing tumor cells autophagy levels to promote CRC progression. It may provide a new idea and mechanism for answering why the immune monoclonal antibody treatment is ineffective in cancer patients.
Journal • PD(L)-1 Biomarker • IO biomarker • Tumor cell
|
PD-1 overexpression • PD-1 expression
|
oxaliplatin
9ms
Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma. (PubMed, Front Immunol)
The combination treatment of Abrine and anti-PD-1 antibody has a synergistic effect on suppressing the tumor growth through up-regulating CD4 or CD8 T cells, down-regulating the Foxp3 Treg cells, and inhibiting the expression of IDO1, CD47, and PD-L1. Overall, this study reveals that Abrine as an IDO1 inhibitor has an inhibition effect on immune escape and has a synergistic effect with the anti-PD-1 antibody on the treatment of HCC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD47 (CD47 Molecule) • JAK1 (Janus Kinase 1) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • PD-1 overexpression • IDO1 expression • IFNG expression
10ms
Increased PD-1 Expression of Bone marrow T cells in Acute Myeloid Leukemia Patients After Stem Cell Transplantation, and Its Association with Overall Survival. (PubMed, Ann Clin Biochem)
In conclusion, patients who underwent allo-SCT exhibited high PD-1 expression, suggesting that allo-SCT increases PD-1 expression on T cells, and the patients with high PD-1 expression on CD8+T cells after allo-SCT showed the poor prognosis. For these patients, PD-1 blockade could be an immunotherapeutic strategy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CD4 (CD4 Molecule)
|
PD-L1 expression • PD-1 overexpression • PD-1 expression • CD8 expression • PD-1-L • PD-1 underexpression
10ms
Humanized mouse models for preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers (EACR 2023)
FACS analysis of xenograft tumors revealed an increased percentage of tumor infiltrating T-cells. We identified a set of CDX and PDX models without interference with parallel injection of PBMC, T- or NK-cell preparations for the evaluation of immune cell engagers and other cell therapies.ConclusionWe established human tumor-immune-cell models of different entities using CDX or PDX in combination with different donor derived immune cell subsets as effector cells.These models allow preclinical, translational studies on tumor immune biology as well as evaluation of new therapies, drug combinations and biomarker identification and validation.
Preclinical • PD(L)-1 Biomarker • IO biomarker • Immune cell
|
PD-1 (Programmed cell death 1) • CD34 (CD34 molecule)
|
PD-1 overexpression • PD-1 expression
10ms
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1)
|
PD-1 overexpression
10ms
BLEACH&STAIN 15-marker multiplexed imaging in 3098 human carcinomas reveals 6 major PD-L1-driven immune phenotypes with distinct spatial orchestration. (PubMed, Mol Cancer Res)
In conclusion, our deep learning-based BLEACH&STAIN framework facilitates rapid and comprehensive assessment of more than 60 spatially orchestrated immune cell subpopulations and its prognostic relevance. Implications: The development of an easy-to-use high-throughput 15+1 multiplex fluorescence approach facilitates the in-depth understanding of the immune tumor microenvironment and enables to study the prognostic relevance of more than 130 immune cell subpopulations.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • FOXP3 (Forkhead Box P3) • ITGAX (Integrin Subunit Alpha X) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
PD-1 overexpression • PD-1 expression
11ms
S100a9 deficiency accelerates MDS-associated tumor escape via PD-1/PD-L1 overexpression. (PubMed, Acta Biochim Biophys Sin (Shanghai))
Our findings indicate the possible mechanisms by which anti-PD-1 agents may contribute to the treatment of MDS. These insights may provide mutation-specific treatment as a supplementary therapy for MDS patients with high-risk mutations, such as TP53, N-RAS or other complex mutations.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PD-1 (Programmed cell death 1) • S100A9 (S100 Calcium Binding Protein A9)
|
TP53 mutation • PD-L1 overexpression • PD-1 overexpression • S100A9 expression
12ms
Paeonol inhibits melanoma growth by targeting PD1 through upregulation of miR-139-5p. (PubMed, Biochem Biophys Res Commun)
Dual-luciferase assays indicated that miR-139-5p interacted with the 3' untranslated region (3'-UTR) of PD1. These results showed that paeonol alleviates PD1-mediated antitumor immunity by reducing miR-139-5p expression and demonstrated a novel mechanism for melanoma immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • MIR139 (MicroRNA 139)
|
PD-1 overexpression • PD-1 expression • PD-1-L • PD-1 underexpression • miR-139-5p expression
12ms
Genetically Engineered PD-1 Displaying Nanovesicles for Synergistic Checkpoint Blockades and Chemo-Metabolic Therapy Against Non-Small Cell Lung Cancer. (PubMed, Acta Biomater)
We further loaded P-NVs with 2-deoxy-D-glucose (2-DG) and doxorubicin (DOX), and found that these drugs co-loaded P-NVs efficiently shrank lung cancers in mouse models for both allograft and autochthonous tumor. 2-DG loaded nanoparticles thus activate anti-tumor activities of T cells in the tumor microenvironment. Our work thus highlights the promising antitumor activity of PDG-NVs, which warrants further clinical evaluation.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
|
PD-1 (Programmed cell death 1)
|
PD-L1 expression • PD-1 overexpression • PD-1 expression
|
doxorubicin hydrochloride
1year
Preclinical models for translational immuno-oncology research: Rare patient-derived xenografts on humanized mice (AACR 2023)
Finally, we evaluated the functionality of the model by the treatment with checkpoint inhibitors like Ipilimumab (Ipi), Nivolumab (Nivo) or Pembrolizumab (Pembro). Treatment with Ipi, Nivo or Pembro led to a minor tumor growth delay. Response to checkpoint inhibitors showed a correlation to innate immune response and PD-L1 expression of PDX and could further be increased by combination with radiotherapy.ConclusionsOur humanized immune-PDX models enable appropriate preclinical translational research on tumor immune biology and the evaluation of new therapies and combinations, as well as the identification and validation of biomarkers for immune therapy, especially in rare PDX models.
Preclinical • PD(L)-1 Biomarker • IO biomarker • Immuno-oncology
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • PD-1 overexpression • PD-1 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
1year
Loss of HSPD1 induces cellular plasticity in triple-negative breast cancer cells (AACR 2023)
Conclusion Our results suggest that loss of HSPDI in the context TNBC cells may promotes oncogenic transformation to an intermediary luminal progenitor phenotype that gains differentiation plasticity based on the upregulation of Estrogen-receptors signaling pathways. Ongoing analyses will be performed to identify the possible links between loss of HSPD1 and key transcription factors that define mammary epithelial cell differentiation.
BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor) • BRCA (Breast cancer early onset) • HSPD1 (Heat Shock Protein Family D (Hsp60) Member 1)
|
PD-1 overexpression • PD-1 expression • AR expression
1year
YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity. (PubMed, Front Pharmacol)
In conclusion, YIV-906 modulates adaptive immunity by activating T effector cells mainly through its action on SHP1/2. YIV-906 could also facilitate immune checkpoint blockade therapy or CAR-T cell therapy for cancer treatment.
Journal • CAR T-Cell Therapy • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
|
PD-L1 (Programmed death ligand 1) • CD19 (CD19 Molecule) • CD69 (CD69 Molecule) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
|
PD-L1 overexpression • PD-1 overexpression • CD19 expression
|
YIV-906
over1year
Leptin receptor (Ob-R)/leptin axis significantly modulates tumour-infiltrating lymphocytes (TILs) and PD-1 expression in early HER2+ breast cancer (BC) emerging as a new surrogate marker for immunotherapy (SABCS 2022)
This multidisciplinary clinical study decodes for the first time how obesity, through the OB-R/leptin axis, might activate TILs but apparently dysfunctional as it is not translated into higher pCR; probably due to the presence of exhausted features such as high PD-1 expression. The role of Ob-R together with PD-1 as a potential biomarker for immunotherapy should be further explored.
Tumor-Infiltrating Lymphocyte • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-1 (Programmed cell death 1) • LEP (Leptin)
|
HER-2 expression • PD-1 overexpression • PD-1 expression • PD-1 elevation
over1year
Molecular profile changes in castrate resistant prostate cancer patients pre and post-abiraterone/prednisone treatment. (PubMed, Mol Cancer Res)
We also found evidence of resistance via PD1 overexpression in responders. Implications: Finally, we identified candidates drugs to reverse AA/P resistance : topoisomerase inhibitors and drugs targeting the cell cycle via the MYC/AURKA/AURKB/TOP2A and/or PI3K/AKT1/MTOR pathways.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • TOP2A (DNA topoisomerase 2-alpha) • AURKA (Aurora kinase A) • AURKB (Aurora Kinase B) • ITGAM (Integrin, alpha M)
|
PD-1 overexpression
|
abiraterone acetate • prednisone
over1year
Critical evaluation of an autologous peripheral blood mononuclear cell-based humanized cancer model. (PubMed, PLoS One)
In summary, the iPDX models reproduced key features of the corresponding human tumor. The observed variability and high PD-1 expression are important considerations that need to be addressed in order to develop a reproducible model system.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)
|
PD-1 overexpression • PD-1 expression • PD-1 elevation
over1year
Influence of PD-1/PD-L1 on immune micro-environment in oral leukoplakia and oral squamous cell carcinomas. (PubMed, Oral Dis)
The PD-1/PD-L1 may induce immune suppression in OLK and accelerate the progress of malignant transformation.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • PD-1 overexpression • PD-1 expression • CD8 expression • PD-1 elevation • PD-1-L • PD-1 underexpression • FOXP3 expression
over1year
Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis. (PubMed, J Hematol Oncol)
This study suggests that GPD1 may act as a novel tumor suppressor in bladder cancer. Pharmacological activation of GPD1 is a potential therapeutic approach for bladder cancer.
Journal
|
TRPV2 (Transient Receptor Potential Cation Channel Subfamily V Member 2)
|
PD-1 overexpression • PD-1 expression
over1year
Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma. (PubMed, Front Immunol)
Additionally, as a GUSB inhibitor, amoxapine can reduce the progression of human HCC cells, and was an effective treatment for HCC and improved the sensitivity of anti-PD1 therapy. In summary, this study reveals that increased GUSB downregulates PD-L1 expression by promoting miR-513a-5p, leading to primary resistance to anti-PD1 treatment in HCC, and amoxapine enhances the sensitivity of anti-PD1 therapy by inhibiting GUSB, providing a new strategy and method for improving the efficacy of anti-PD1 therapy and bringing new prospects for therapy of HCC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
MIR513A1 (MicroRNA 513a-1)
|
PD-L1 expression • PD-1 overexpression
almost2years
The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt. (PubMed, J Egypt Natl Canc Inst)
Positive ALK expression and EGFR-mutations are independent adverse predictors of NSCLC. Overexpression of PD-1/PD-L1 is not a significant prognostic marker in NSCLC patients receiving chemotherapy, making them susceptible to immunotherapy. Since PD-1/PD-L1 expression is independent to oncogenic driver mutations, future studies into specific immune checkpoint inhibitors combined with targeted therapies for individualized treatment of NSCLC is warranted. Positive ALK expression and EGFR mutations are independent risk factors for NSCLC. Overexpression of PD-1/PD-L1 is not a significant prognostic factor in patients with NSCLC who are receiving chemotherapy, making them immunotherapy susceptible. Given that PD-1/PD-L1 expression is not dependent on oncogenic driver mutations, additional research into specific immune checkpoint inhibitors in combination with targeted therapies for the treatment of NSCLC on an individual basis is warranted.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • EGFR mutation • ALK positive • EGFR expression • EGFR wild-type • ALK mutation • ROS1 positive • PD-1 overexpression • ROS1 rearrangement • PD-1 expression • ALK negative • ROS1 expression
almost2years
Characterization of the Immune Cell Infiltration Landscape Uncovers Prognostic and Immunogenic Characteristics in Lung Adenocarcinoma. (PubMed, Front Genet)
The TMEscore-low subtype showed overexpression of PD-1, CTLA4, and associations of other markers of sensitivity to immunotherapy, including TMB, immunophenoscore (IPS) analysis, and tumor immune dysfunction and exclusion (TIDE) algorithm. Conclusively, TMEscore is a promising and reliable biomarker to distinguish the prognosis, the molecular and immune characteristics, and the benefit from ICIs treatments in LUAD.
Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
PD-1 overexpression • PD-1 expression • CTLA4 expression • CTLA4 underexpression
almost2years
S100A9 DEFICIENCY ACCELERATES MDS ASSOCIATED TUMOR ESCAPE VIA PD-1/PD-L1 OVEREXPRESSION (EHA 2022)
Conclusion Our findings indicated the possible mechanisms anti-PD-1 agents may contribute to the treatment of MDS. These insights may provide more accurate treatment as the supplementary therapy for MDS patients with high risk mutations, like TP53, N-RAS or other complex mutations.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PD-1 (Programmed cell death 1) • S100A9 (S100 Calcium Binding Protein A9)
|
TP53 mutation • PD-L1 overexpression • PD-1 overexpression • S100A9 expression